M&A Deal Summary

Novartis Acquires Chiron

On April 20, 2006, Novartis acquired life science company Chiron

Acquisition Highlights
  • This is Novartis’ 2nd transaction in the Life Science sector.
  • This is Novartis’ 2nd transaction in the United States.
  • This is Novartis’ 1st transaction in California.

M&A Deal Summary
Date 2006-04-20
Target Chiron
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition

Target

Chiron

Emeryville, California, United States
Chiron Corporation was a multinational biotechnology firm based in Emeryville, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 46.7B USD (2023)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 2 of 32
Sector (Life Science) 2 of 26
Type (Add-on Acquisition) 2 of 28
State (California) 1 of 5
Country (United States) 2 of 24
Year (2006) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-02-21 Eon Labs

Laurelton, New York, United States

Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-06-04 Protez Pharmaceuticals

Malvem, Pennsylvania, United States

Protez Pharmaceuticals, Inc. is a drug development company focused on novel antibiotics for the hospital market. Key program areas for Protez include a breakthrough broad spectrum carbapenem and two combination strategies for product line extensions of multiple established antibiotics.

Buy $400M
Mergr

Product

Company

Legal